Company intelligence / Profile preview
Janssen Research & Development
- Ownership
- Private
- Employees
- ~28000
- Development stage
- Other
Overview
Janssen Research & Development has developed and commercialized a robust portfolio of therapies across multiple disease areas, leveraging expertise in biologics, small molecules, and vaccines. The company is recognized for launching over 50 new biological medicines and contributing to approved therapies for significant global diseases, including COVID-19 (e.g., vaccine development supported by BARDA funding). Its portfolio spans from early development to commercialization.
- Therapeutic areas
- ImmunologyMetabolic DisordersInfectious DiseasesCardiovascularOncologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyBiologicVaccineCell therapy
- Industry
- Pharma
Drug pipeline
126 assets125 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Janssen Research & Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Janssen Research & Development.